Physician profile
Jennifer Bourke
NPI 1952012601
$704.72
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $256 · 2024: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $138.75 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $105.66 | 2023-2024 | Keytruda, Prevymis, Dificid |
| Daiichi Sankyo INC. | $79.90 | 2023-2024 | Vanflyta |
| Sobi, INC | $57.35 | 2024 | |
| Melinta Therapeutics, LLC | $53.61 | 2024 | Rezzayo, Kimyrsa |
| Takeda Pharmaceuticals U.S.A., INC. | $50.27 | 2023-2024 | Iclusig |
| Emd Serono, INC. | $39.78 | 2024 | |
| Genentech USA, INC. | $27.03 | 2024 | Venclexta |
| Genmab U.S., INC. | $25.84 | 2023 | Epkinly |
| Pharmaessentia USA Corporation | $25.60 | 2024 | Besremi |
| Celgene Corporation | $23.76 | 2023 | Reblozyl |
| Pfizer INC. | $23.42 | 2024 | |
| Janssen Biotech, INC. | $19.20 | 2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $18.70 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.85 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bourke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.